M. Kurt

Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.

J. Ajani, S. Kanters, I. Kim, 2022, European journal of cancer.

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial

A. Italiano, V. Rondeau, C. Bellera, 2021, ESMO open.

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067

S. Kotapati, A. Moshyk, V. Paly, 2022, PharmacoEconomics - Open.

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma

O. Michielin, J. Borrill, M. Butler, 2022, MDM policy & practice.

What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma

J. Borrill, E. Fenwick, B. Malcolm, 2021, PharmacoEconomics.

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma

B. McGregor, F. Ejzykowicz, M. Dyer, 2023, Journal of comparative effectiveness research.

PDG5 Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC)

F. Ejzykowicz, B. Malcolm, J. May, 2020 .

PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update

S. Ho, F. Ejzykowicz, B. Malcolm, 2020 .